DEF 14A: Surrozen, Inc. Sets Date for 2025 Annual Stockholder Meeting, Outlines Key Proposals

Surrozen, Inc. announces its 2025 annual meeting of stockholders to be held virtually on May 14, 2025, featuring proposals for director elections and ratification of the company's independent accounting firm.

Summary

• Surrozen, Inc. will hold its 2025 annual meeting of stockholders on May 14, 2025, at 10:00 a.m. Pacific Time, as a virtual meeting.
• Stockholders of record as of March 19, 2025, are entitled to vote.
• The meeting will address the election of Anna Berkenblit, Eric Bjerkholt, and Tim Kutzkey as Class I directors, each serving until the 2028 annual meeting.
• The stockholders will also vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2025.
• The Board of Directors recommends voting 'FOR' the election of the director nominees and 'FOR' the ratification of Ernst & Young LLP's appointment.
• The proxy statement and annual report are available online at www.proxyvote.com.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, outlining the agenda for the annual meeting and related corporate governance matters. The sentiment is neutral to slightly positive, reflecting the company's adherence to standard practices and ongoing efforts to engage with stockholders.

Positives

• The company is utilizing a virtual meeting format to enhance accessibility and reduce costs for stockholders.
• The Board is recommending experienced and qualified individuals for election as directors.
• The Audit Committee has pre-approved all services performed by Ernst & Young LLP, ensuring auditor independence.
• The company has adopted Corporate Governance Guidelines and a Code of Business Conduct and Ethics to promote ethical behavior and accountability.
• The company has a compensation recoupment policy in place.

Risks

• Failure to ratify the appointment of Ernst & Young LLP could necessitate the selection of a different independent registered public accounting firm.
• The limitation of liability and indemnification provisions in the Certificate of Incorporation and Bylaws may discourage stockholders from bringing lawsuits against directors.
• The company's future performance depends on achieving corporate performance goals related to the development of product candidates and adherence to established budgets.

Future Outlook

The company anticipates a second closing for the remaining $98.6 million of a private placement, subject to FDA clearance of the Investigational New Drug Application for SZN-8141, expected in 2026.

Management Comments

• On behalf of the Board of Directors and management, it is my pleasure to express our appreciation for your continued support, said Craig Parker, President, Chief Executive Officer and Director.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including the election of directors, ratification of auditors, and disclosure of executive compensation and related party transactions. The virtual meeting format aligns with a growing trend in corporate governance to enhance accessibility and reduce costs.

Comparison to Industry Standards

• The director compensation structure, including cash retainers and equity grants, is generally consistent with industry practices for similarly sized biotechnology companies.
• The audit fee paid to Ernst & Young LLP is within the typical range for companies of Surrozen's size and complexity.
• The company's corporate governance guidelines and committee charters align with best practices recommended by institutional investors and proxy advisory firms.
• The company's executive compensation program, including base salaries, bonus targets, and equity incentives, is designed to attract and retain qualified executives and align their interests with those of stockholders.

Related Party Transactions

• The company entered into a research collaboration agreement with TCGFB, Inc., a company founded and controlled by entities affiliated with The Column Group, a significant stockholder.
• Tim Kutzkey, a member of the Board, is a Managing Partner at The Column Group.
• The company entered into a sublease agreement with Nura Bio, Inc., where Tim Kutzkey serves as the chairman of the board of directors.
• The company engaged in private placements in April 2024 and March 2025, with participation from entities affiliated with The Column Group and certain executive officers and directors.

Stakeholder Impact

• Stockholders have the opportunity to vote on key corporate governance matters, including the election of directors and the ratification of the independent accounting firm.
• The company's corporate governance practices and executive compensation programs are designed to align the interests of management with those of stockholders.
• The company's related party transactions are subject to review and approval by the audit committee to ensure fairness and transparency.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will proceed with the annual meeting on May 14, 2025.
• The company will continue to monitor and update its corporate governance practices and policies.
• The company will seek FDA clearance for SZN-8141 to proceed with the second tranche of the private placement.

Key Dates

Keywords

annual meeting, proxy statement, directors, Ernst & Young, stockholders, corporate governance, audit committee, executive compensation, related party transactions